Just published with the #AACR26 New Drugs on the Horizon session: TNG961 Is a Selective Oral HBS1L Molecular Glue Degrader for the Treatment of FOCAD-Deleted Cancers - by Hilary Nicholson and colleagues
https://
aacrjournals.org/cancerdiscover
y/article/doi/10.1158/2159-8290.CD-26-0040
…